Program
opevesostat
Also written as “Opevesostat”, “MK-5684” and “ODM-208”.
Its studies are mostly in Prostatic Neoplasms · Prostatic Neoplasms, Castration-Resistant · Neoplasms · Kidney Failure, Chronic, led by 2 companies.
Drug pageOpevesostat: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 124 open or running | phase 3since Nov 13, 2023 | Oct 23, 2023 | Nov 4, 2027phase 2 · NCT06979596 |
| Orion Corporation, Orion Pharmaits history only | 11 open or running | phase 2since Feb 12, 2018 | Feb 12, 2018 | none ahead |
- Named in Merck’s own pipeline as
opevesostat (MK-5684)
, phase 3, as of Nov 2, 2026 (source).
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseMerck licensed it from Orion, for worldwide rights, in place of their co-development.Announced Jul 1, 2024 · Source: Merck, Jul 1, 2024
History and studies of Merck only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Aug 6, 2023Named opevesostatINNProposed as its International Nonproprietary Name in WHO's List 129 · before, MK-5684, ODM-208
- Oct 23, 2023First study: phase 1 study in Prostatic NeoplasmsFirst studyNCT06104449 · 7 enrolled · Japan
- Nov 13, 20232 phase 3 studiesNCT06136650, NCT06136624
- Nov 13, 2023Phase 1 study in Prostatic NeoplasmsNCT06136598 · 14 enrolled · China
- Apr 3, 2024Phase 2 study in Prostatic Neoplasms, Castration-ResistantNCT06353386 · 220 enrolled · United States, Australia, Canada and more
- Jul 1, 2024Merck licensed it from OrionLicenseWorldwide rights, in place of their co-development · announced · Merck
- Aug 12, 20242 phase 1 studies in Prostatic NeoplasmsNCT06554639, NCT06566989
- Oct 7, 2024Phase 1 study in HealthyNCT06633419 · 14 enrolled · United States
- Feb 3, 20252 phase 1 studiesNCT06814132, NCT06860243
- May 13, 2025Phase 2 study in NeoplasmsNCT06979596 · 250 planned · United States, Argentina, Brazil and more
- Apr 17, 2026Phase 1 study in HealthyNCT07548606 · 14 enrolled · United States
- Nov 5, 2026Primary completion moved from 2028-08-02 to 2028-11-30Date moved laterphase 3 · +4 months · NCT06136624
Ahead
- Nov 4, 2027Primary completion: phase 2 study in NeoplasmsNCT06979596
- May 10, 2028Primary completion: phase 3 study in Prostatic NeoplasmsNCT06136650
- Nov 30, 2028Primary completion: phase 3 study in Prostate Cancer MetastaticNCT06136624
- Jan 15, 2029Primary completion: phase 2 study in Prostatic Neoplasms, Castration-ResistantNCT06353386
TargetBeta
“An orally bioavailable, non-steroidal, selective inhibitor of the enzyme cytochrome 450 side-chain cleavage (scc) (CYP11A1), with potential antineoplastic activity. Upon oral administration, opevesostat targets, binds to and inhibits the activity of CYP11A1. This prevents the synthesis of all ste…”NCIt, read by Claude
“An orally bioavailable, non-steroidal, selective inhibitor of the enzyme cytochrome 450 side-chain cleavage (scc) (CYP11A1), ”NCIt, by rule
Other programs on CYP11A1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| CYP11A1 Inhibitor ACE-232rule | acerand-therapeutics-hong-kong-limited | phase 1 | 1 |
Studies
All 12 Merck leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07548606Healthy · United States | 1 | Completed | Jun 1, 2026 | 14 |
| NCT06979596Neoplasms · United States, Argentina, Brazil and more | 2 | Recruiting | Nov 4, 2027 | 250 |
| NCT06860243Hepatic Impairment · United States | 1 | Completed | Feb 9, 2026 | 16 |
| NCT06814132Kidney Failure, Chronic · United States | 1 | Completed | Oct 4, 2025 | 24 |
| NCT06633419Healthy · United States | 1 | Completed | Feb 12, 2025 | 14 |
| NCT06566989Prostatic Neoplasms · United Kingdom | 1 | Completed | Oct 17, 2024 | 8 |
| NCT06554639Prostatic Neoplasms · United States | 1 | Completed | Aug 5, 2024 | 12 |
| NCT06353386Prostatic Neoplasms, Castration-Resistant · United States, Australia, Canada and more | 2 | Active, not recruiting | Jan 15, 2029 | 220 |
| NCT06136650Prostatic Neoplasms · United States, Australia, Brazil and more | 3 | Recruiting | May 10, 2028 | 1,314 |
| NCT06136624Prostate Cancer Metastatic · United States, Argentina, Australia and more | 3 | Recruiting | Nov 30, 2028 | 1,310 |
| NCT06136598Prostatic Neoplasms · China | 1 | Completed | Mar 9, 2026 | 14 |
| NCT06104449Prostatic Neoplasms · Japan | 1 | Completed | Feb 20, 2026 | 7 |
How it is read
Names in the registry
- “Opevesostat”, 9 entries
- “MK-5684”, 2 entries
- “ODM-208”, 1 entry
- “[¹⁴C]Opevesostat”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 7 studies
- Prostatic Neoplasms, Castration-Resistant, 1 study
- Neoplasms, 1 study
- Kidney Failure, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.